{
    "clinical_study": {
        "@rank": "89127", 
        "arm_group": [
            {
                "arm_group_label": "Concurrent chemoradiotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Capecitabine neoadjuvant concurrent radiochemotherapy and XELOX adjuvant therapy"
            }, 
            {
                "arm_group_label": "Sequential therapy", 
                "arm_group_type": "Experimental", 
                "description": "XELOX/capecitabine/XELOX neoadjuvant chemo-chemoradio-chemo sequential therapy and XELOX adjuvant therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "Compared curative effect\uff0csafety and compliance between concurrent chemoradiotherapy and\n      chemo-chemoradio-chemo sequential therapy in locally advanced mid/low rectal cancer."
        }, 
        "brief_title": "Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Rectal Cancer", 
        "condition_browse": {
            "mesh_term": "Rectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The patients were divided into two arms according to the defined conditions (pathology\n      rectal adenocarcinoma\uff1bdistal distance of tumor from anal verge < 10cm\uff1bTNM staging\n      T3-4N0-2\uff1bno distant metastasis\uff1bKarnofsky score\u226570) in this prospective, single center, open,\n      non randomized trail (arm A:concurrent chemoradiotherapy, arm B:sequential therapy).\n      Regimens:Arm A:50Gy,2Gy/day per time, 5 days a week, for 5 weeks. +capecitabine 850mg/m2\n      bid on the day accept radiotherapy. Rest for 8 weeks. Arm B: XELOX 2 cycles (oxaliplatin\n      130mg/m2 ivgtt 2-6h day 1, capecitabine 1000 mg/m2 Bid day 1-14, repeat every 3 weeks ) \u2192\n      50Gy,2Gy/day per time, 5 days a week, for 5 weeks.+capecitabine 850mg/m2 bid on the day\n      accept radiotherapy \u2192 XELOX 1 cycle. Rest for 2 weeks. Evaluate pre chemotherapy, pre\n      radiotherapy and pre surgery individually. Surgeries followed TME(total mesorectal excision)\n      and PANP(pelvic autonomic nerve preservation) for patients in both arms. Take pathological\n      evaluation of tumors. Take XELOX therapy till 6-8 cycles(pre and after surgery total).\n      Follow up according the schedule."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathology rectal adenocarcinoma\n\n          -  Distal distance of tumor from anal verge < 10cm\n\n          -  TNM staging T3-4N0-2(MRI)\n\n          -  No distant metastasis\n\n          -  Karnofsky score\u226570\n\n          -  Female patients need contraception during the test\n\n          -  Postmenopausal women for at least 12 months, expect pregnancy possibility\n\n          -  Patients did not receive chemotherapy, radiotherapy in any form before\n\n          -  No other severe related diseases (such as other tumor, severe cardiac and central\n             nervous system diseases, etc.)\n\n        Exclusion Criteria:\n\n          -  Be treated by radiotherapy, chemotherapy or tumor biological therapy before\n\n          -  Received immunosuppressive therapy (including corticosteroids)\n\n          -  Participated in other clinical trial(s) in 1 month\n\n          -  With malignant tumor of colon\n\n          -  Peripheral neuropathy (WHO I level and above)\n\n          -  Neurological or psychiatric abnormalities affecting cognition , including central\n             nervous system metastasis\n\n          -  Severe allergies or allergic history\n\n          -  Severe pulmonary or heart disease\n\n          -  Pregnant or lactation or refuse contraception during the test\n\n          -  Suffering other malignant tumors in past"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022852", 
            "org_study_id": "HarbinMU-BCui-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Concurrent chemoradiotherapy", 
                "description": "50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequential therapy", 
                "description": "XELOX 2 cycles (oxaliplatin 130mg/m2  ivgtt  2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) \u2192 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy \u2192 XELOX 1 cycle. Rest for 2 weeks and surgery followed.", 
                "intervention_name": "XELOX", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Capecitabine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rectal Cancer", 
            "Concurrent Chemoradiotherapy", 
            "Sequential Therapy"
        ], 
        "lastchanged_date": "December 23, 2013", 
        "location": {
            "contact": {
                "email": "13351112888@163.com", 
                "last_name": "Binbin Cui, MD", 
                "phone": "13351112888"
            }, 
            "facility": {
                "address": {
                    "city": "Harbin", 
                    "country": "China", 
                    "state": "Heilongjiang", 
                    "zip": "150081"
                }, 
                "name": "Harbin Medical University Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "Binbin Cui, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Neoadjuvant Chemo-chemoradio-chemo Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer: a Phase II Trial", 
        "other_outcome": {
            "measure": "Compliance", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "overall_contact": {
            "email": "13351112888@163.com", 
            "last_name": "Binbin Cui, MD", 
            "phone": "+86 13351112888"
        }, 
        "overall_official": {
            "affiliation": "Department of Abdominal Surgery, Harbin Medical University Cancer Hospital", 
            "last_name": "Binbin Cui, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease free survival", 
            "safety_issue": "Yes", 
            "time_frame": "3-year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022852"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Harbin Medical University", 
            "investigator_full_name": "Binbin Cui", 
            "investigator_title": "Director of Abdominal Surgery Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Local recurrence rate", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Safety: Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "R0 resection rate", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Pathologic complete response", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Harbin Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Harbin Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}